Home/ Stocks/ INBX

Inhibrx Biosciences, Inc. Common Stock

INBX XNAS

$87.01 -4.24 (-4.65%) ▼ 15-min delayed

Open

$90.08

High

$92.73

Low

$85.48

Volume

417.4K

Market Cap

$1.28B

About Inhibrx Biosciences, Inc. Common Stock

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 110 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-33,441,000	$-2.15
FY 2025	$1.30M	$-140,055,000	$-9.04
Q3 2025	$0	$-35,256,000	$-2.28
Q1 2025	$0	$-43,311,000	$-2.80

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 11, 2026

Calendar →

TickerDaily Coverage

Why Is Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Up 76.6% Today?

Market News Sarah Mitchell · Apr 22, 2026

Inhibrx Biosciences (INBX) stock ripped higher 76.6% on Wednesday, April 22, 2026, closing at...

Stock Market Today, April 24, 2026: Microcaps Surge on Biotech Optimism

Market News David Brooks · Apr 24, 2026

Friday, April 24, 2026 marked the end of a remarkable week for speculative growth stocks, with...

View All Coverage →

Get INBX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Inhibrx Biosciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.